Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 21
2004 24
2005 42
2006 32
2007 54
2008 55
2009 47
2010 81
2011 80
2012 85
2013 87
2014 123
2015 117
2016 92
2017 108
2018 136
2019 145
2020 185
2021 191
2022 241
2023 212
2024 215
2025 227
2026 97

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,403 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB; NOTUS Study Investigators. Bhatt SP, et al. Among authors: lu x. N Engl J Med. 2024 Jun 27;390(24):2274-2283. doi: 10.1056/NEJMoa2401304. Epub 2024 May 20. N Engl J Med. 2024. PMID: 38767614 Clinical Trial.
Lymphopenia in sepsis: a narrative review.
Wang Z, Zhang W, Chen L, Lu X, Tu Y. Wang Z, et al. Among authors: lu x. Crit Care. 2024 Sep 20;28(1):315. doi: 10.1186/s13054-024-05099-4. Crit Care. 2024. PMID: 39304908 Free PMC article. Review.
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB. Bhatt SP, et al. Among authors: lu x. Lancet Respir Med. 2025 Mar;13(3):234-243. doi: 10.1016/S2213-2600(24)00409-0. Epub 2025 Jan 31. Lancet Respir Med. 2025. PMID: 39900091 Clinical Trial.
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, Omiyale AO, Jacobs BA, Lord SR, Norris-Bulpitt S, Dobbie ST, Griffiths L, Ramirez KA, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Van den Eynde BJ, Karydis I, Schuster-Böckler B, Middleton MR, Lu X; LUD2015-005 Project Team. Carroll TM, et al. Among authors: lu x. Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. doi: 10.1016/j.ccell.2023.06.006. Cancer Cell. 2023. PMID: 37433281 Free PMC article.
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM. Bhatt SP, et al. Among authors: lu x. Respir Med. 2025 Jan;236:107846. doi: 10.1016/j.rmed.2024.107846. Epub 2024 Oct 30. Respir Med. 2025. PMID: 39481660 Free article. Clinical Trial.
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB. Bhatt SP, et al. Among authors: lu x. Chest. 2025 Jul;168(1):56-66. doi: 10.1016/j.chest.2025.01.029. Epub 2025 Jan 31. Chest. 2025. PMID: 39894389 Free article. Clinical Trial.
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.
Christenson SA, Hanania NA, Bhatt SP, Bafadhel M, Rabe KF, Vogelmeier CF, Papi A, Singh D, Laws E, Dakin P, Bansal A, Lu X, Bauer D, Maloney J, Robinson LB, Abdulai RM. Christenson SA, et al. Among authors: lu x. Lancet Respir Med. 2025 Aug;13(8):687-697. doi: 10.1016/S2213-2600(25)00044-X. Epub 2025 Jul 9. Lancet Respir Med. 2025. PMID: 40651490 Free article. Clinical Trial.
iMeta Conference 2025: Creating high-impact international journals.
Zhu Z, Zhang L, Yao X, Zeng M, Wang Y, Luo H, Zhou Y, Zhang T, Xun J, Bai D, Yang H, Xu S, Zhou Y, Gao Y, Xu J, Han W, Shen Z, Zhang B, Ma T, Wan XL, Ma C, Hui F, Bai H, Bai L, Bai Q, Bao Q, Cao G, Cao P, Cao Q, Chen H, Chen J, Chen J, Chen L, Chen T, Chen Y, Cui H, Dai S, Dai XJ, Dai X, Dang Y, Deng L, Deng Y, Ding X, Dong B, Dong L, Dou S, Du H, Fang Z, Feng X, Fu M, Gao Y, Gong W, Guo X, Han W, Hao Z, He ZG, Hu H, Hu H, Hu X, Huang L, Huang X, Huang X, Hui H, Jia D, Jiang A, Jiang D, Jiang K, Jiang D, Jin Y, Lai K, Li C, Li F, Li F, Li J, Li J, Li J, Li K, Li L, Li M, Li P, Li P, Li R, Li S, Li S, Li W, Li W, Li X, Li X, Li X, Liang Q, Liao X, Liu B, Liu C, Liu C, Liu D, Liu F, Liu J, Liu J, Liu S, Liu T, Liu W, Liu Y, Liu Y, Liu Y, Liu Y, Liu Y, Liu Z, Liu Z, Lu X, Luo X, Ma G, Meng J, Meng Y, Miao R, Miao L, Ni Y, Niu D, Niu T, Pan H, Qin G, Qiu T, Qiu Y, Qu H, Qu L, Ren N, Sun Q, Shang R, She P, Shen X, Shi B, Shu Y, Song J, Song W, Su Q, Sun Q, Sun Y, Sun Z, Tang B, Tang D, Tang H, Tao Y, Teng T, Tu Y, Wang C, Wang H, Wang Y, Wang C, Wang D, Wang G, Wang J, Wang K, Wang M, Wang S, Wang S, Wang X, Wang XC, Wang Y, Wang J, Wang Z, Wang W, Wei Y, Xu W, Wu F, Wu J, Wu S,… See abstract for full author list ➔ Zhu Z, et al. Among authors: lu x. Imeta. 2025 Oct 15;4(6):e70086. doi: 10.1002/imt2.70086. eCollection 2025 Dec. Imeta. 2025. PMID: 41472845 Free PMC article.
2,403 results